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OsteoclastogenesisWe examined whether alteration of PP2A Ca expression in osteoblasts is involved in osteoclast dif-
ferentiation. Reduction of PP2A Ca in MC3T3-E1 cells (shPP2A) decreased receptor activator of
nuclear factor jB ligand (RANKL) expression and increased osteoprotegerin (OPG) expression. The
conditioned medium from shPP2A cells failed to induce NFATc1 as well as the expression of osteo-
clast marker genes cathepsin K and osteoclast-associated receptor (OSCAR) in bone marrow macro-
phage cells. Treatment of bone marrow macrophage cells with the conditioned medium from
shPP2A cells impaired osteoclastogenesis. These results suggest that alteration of PP2A Ca expres-
sion in osteoblasts modulates the expressions of RANKL and OPG, which are involved in osteoclasto-
genesis via the NFATc1 transcription factor.
 2012 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
The bone is a dynamic tissue that provides mechanical support,
physical protection, and a storage site for systemic mineral homeo-
stasis. Bone remodeling is carried out by osteoblasts and osteo-
clasts derived from independent lineages (mesenchymal and
hematopoietic). Osteoblasts produce both stimulatory and inhibi-
tory factors that tightly regulate osteoclast formation and activity
[1–3].
A member of the tumor necrosis factor (TNF) family—receptor
activator of nuclear factor jB ligand (RANKL)—has been shown to
regulate osteoclast differentiation and function directly [4,5].
RANKL is found both as a transmembrane molecule on osteoblasts
and as a secreted molecule—soluble RANKL (sRANKL) [6]. Binding
of RANKL to its receptor, RANK, on the surface of osteoclast precur-
sor cells initiates signals, which leads to osteoclastogenesis. On the
other hand, osteoprotegerin (OPG) is a competitive receptor for
RANKL and has been shown to prevent bone destruction by block-
ing the binding of RANKL with the receptor RANK, thereby inhibit-
ing osteoclast differentiation and activation [4,7]. Therefore,
alterations in the ratio of RANKL/sRANKL to OPG produced from
osteoblasts affect bone turnover and homeostasis by controlling
osteoclastogenesis [8,9].The binding of RANKL/sRANKL to its receptor RANK on the sur-
face of osteoclast precursor cells activates various transcription
factors, including nuclear factor of activated T cells c1 (NFATc1)
[10–12]. In response to an increase in intracellular Ca2+ levels,
NFATc1 is dephosphorylated, which allows NFATc1 to translocate
from the cytoplasm to the nucleus [10,13]. Translocated active
NFATc1 cooperates with other transcription factors to regulate
the expression of many osteoclast-speciﬁc genes such as cathepsin
K, osteoclast-associated receptor (OSCAR), and tartrate-resistant
acid phosphatase (TRAP) [3,14–16].
We recently reported that the reduction of PP2A Ca accelerates
bone formation and osteoblast differentiation through the expres-
sion of bone-related genes [17]. However, it remains unknown
whether reduction of PP2A Ca expression in osteoblasts has an ef-
fect on osteoclast differentiation. The purpose of this study was to
examine whether PP2A Ca expression in osteoblasts is involved in
osteoclast differentiation through RANKL/OPG expression and the
NFATc1 transcription factor.
2. Materials and methods
2.1. Materials
Alpha-modiﬁed Eagle’s minimal essential medium (a-MEM)
was purchased from Invitrogen (Carlsbad, CA). Plastic dishes were
obtained from IWAKI (Chiba, Japan) and fetal bovine serum (FBS)
H. Okamura et al. / FEBS Letters 587 (2013) 48–53 49was purchased from JRH Biosciences (Lenexa, KS). Antibodies
against RANKL (sc-9037) and OPG (sc-8468) were purchased from
Santa Cruz Biotechnology (Santa Cruz, CA), while anti-Gapdh anti-
body, ascorbic acid, b-glycerophosphate, Fast Red TR, and naphthol
AS-MX phosphate were all purchased from Sigma-Aldrich (St.
Louis, MO). The other materials used were of the highest grade
commercially available.
2.2. Cell culture and differentiation
PP2A knockdown (shPP2A) and control (shCont) osteoblastic
cells used in this study have been described previously [17]. Mouse
macrophage RAW264.7 cells were obtained from Riken Cell Bank
(Tsukuba, Japan). shPP2A and shCont cells were cultured in a-
MEM supplemented with 10% fetal bovine serum (FBS) at 37 C un-
der a humidiﬁed atmosphere of 5% CO2. For each assay, the cells
were plated onto 100-mm culture dishes and cultured with differ-
entiation medium (supplemented with 50 lM ascorbic acid and
2 mM b-glycerophosphate) for 7 days. The conditioned medium
was harvested, centrifuged to remove cell debris, ﬁltered through
a 0.45-lm pore membrane ﬁlter (ADVANTEC, Tokyo, Japan), and
stored at 80 C.
2.3. Real-time PCR analysis
Total RNA was extracted using Trizol, as recommended by the
manufacturer (Invitrogen). Real-time PCR of each gene was per-
formed in triplicate for at least three independent experiments.
Real-time PCR was performed with a 7300 Real-time PCR system
(Applied Bio-systems, Carlsbad, CA) using SYBR Premix Ex Taq™
(Takara Bio, Kyoto, Japan). The sequences of the primers were as
follows: Mouse Gapdh (NM_008084): (forward, 761) 50-
TGTGTCCGTCGTCGTGGATCTGA-30, (reverse, 910) 50-TTGCTGTT-
GAAGTCGCAGGAG-30; Mouse cathepsin K (NM_007802): (forward,
620) 50-CAGCAGAACGGAGGCATTGA-30, (reverse, 703) 50-
CTTTGCCGTGGCGTTATACATACA-30; Mouse OSCAR (NM_175632):
(forward, 116) 50-TGCATGCCGTGCTGACTTC-30, (reverse, 223) 50-
AAGGTCACGTTGATCCCAGGAG-30.
2.4. ELISA
ELISA was performed according to the method described by
Hirota et al. [18], with somemodiﬁcations. Brieﬂy, 50 ll of the con-
ditioned media each from shCont and shPP2A cells were separately
dispensed into a polystyrene ELISA plate (Nunc Immuno Module,
Maxisorptype, Nalge Nunc, Rochester, NY). Subsequently, the
plates were dried completely at 37 C. After blocking with 1.5% bo-
vine serum albumin in PBS for 1 h at room temperature (RT), these
plates were incubated with 50-ll total volume of 1:100 diluted
antibody for RANKL or OPG at RT for 1 h. Normal rabbit or goat
IgG was used as a negative control. After washing three times with
PBS, the plate was incubated with 1:500 diluted horseradish perox-
idase-labeled anti-rabbit (for RANKL) or -goat (for OPG) (Biosource
Co., Camarillo, CA) secondary antibodies for 1 h at RT. The plate
was washed 3 times with PBS and then incubated with peroxidase
substrate, 2,20-azino-bis-(3-ethyl-benzthiazolin sulfonate) at RT
for 15 min. The reaction was measured spectrophotometrically at
405 nm.
2.5. Bone marrow cells
All mice studied were reared in our speciﬁc pathogen-free
mouse colony and given food and water ad libitum. Experiments
were humanely conducted under the regulation and permission
of the Animal Care and Use Committee of the University of Toku-
shima, Tokushima, Japan (toku-dobutsu 10051). Bone marrow-de-rived cells from Balb/c mice (4–6 weeks of age) were incubated
with the conditioned medium from shCont and shPP2A cells. The
cultured cells were ﬁxed and stained with TRAP staining solution.
TRAP-positive multinuclear cells containing more than three nuclei
were counted as osteoclasts.
2.6. Immunocytochemistry
Bone marrow macrophage cells were grown on sterile 18-mm
round glass cover slips placed in 60-mm plastic dishes. The cover
slips were incubated for 30 min with an anti-NFATc1 antibody
(BD Biosciences, San Jose, CA) diluted to 1:200 in the blocking solu-
tion. Then, they were incubated for 30 min with Alexa Fluor 488
goat anti-mouse IgG (Invitrogen) secondary antibody, diluted to
1:500 in 4% BSA. After incubation with 10 lg/ml Hoechst 33342
for 30 min, the cover slips were mounted with PermaFluor aqueous
mounting medium (Lipshow, Pittsburgh, PA).
2.7. Statistical analysis
All data was expressed as mean ± SD, and a minimum of three
independent experiments were performed for each assay. Analysis
of variance (ANOVA) was used for statistical analysis. Statistical
signiﬁcance was indicated with ‘‘⁄’’, and P values less than 0.01
were considered signiﬁcant.
3. Results
3.1. Reduction of PP2A Ca attenuates RANKL expression in osteoblasts
To examine whether PP2A Ca expression plays a role in the
expressions of RANKL and OPG in osteoblasts, mRNA isolated from
shCont and shPP2A cells were subjected to real-time PCR using
speciﬁc primers for these transcripts (Fig. 1A). The level of RANKL
was found to be signiﬁcantly lower in shPP2A cells compared to
shCont cells, whereas OPG expression was signiﬁcantly higher in
shPP2A cells compared to shCont cells. Consistent with the real-
time PCR data, the ratio of sRANKL/OPG in the cultured medium
of shPP2A cells was lower than that of shCont cells, as determined
using ELISA (Fig. 1B).3.2. Conditioned medium of shPP2A cells does not induce NFATc1
translocation
During osteoclastogenesis, an activated form of NFATc1 is
known to translocate from the cytoplasm into the nucleus in osteo-
clast precursor cells. Therefore, we investigated whether the condi-
tioned medium from shCont and shPP2A cells could stimulate
NFATc1 translocation. Following a 1 h treatment of bone marrow
macrophage cells with either conditioned medium, the cells were
ﬁxed, permeabilized, and stained using anti-NFATc1 antibody and
Hoechst 33342. We observed green ﬂuorescent signal mostly in
the cytoplasm indicating that NFATc1 expression was localized to
the cytoplasm in untreated cells (Fig. 2, upper panel). When we
treated bone marrow macrophage cells with the conditioned med-
ium from shCont cells, intense green ﬂuorescence for NFATc1 was
observed in the nucleus (Fig. 2, middle panel). In contrast, strong
ﬂuorescence was not observed in the nucleus of the cells treated
with the conditioned medium from shPP2A cells (Fig. 2, bottom pa-
nel). Nuclear staining with Hoechst 33342 was visualized as a red
pseudo-color. Thus, from a merged image, we observed a yellow
ﬂuorescent signal restricted to the nucleus of cells treated with
the conditionedmedium from shCont, but not shPP2A cells, thereby
conﬁrming NFATc1 localization in the nucleus of these cells. Same
results were obtained from another experiment, in which we trea-
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Fig. 1. Expression levels of RANKL and OPG. (A) Total RNA was isolated from shCont or shPP2A cells and examined for RANKL, OPG, and Gapdh transcripts by real-time PCR.
Gene expression was normalized to Gapdh and plotted as the relative value compared to shCont cells (white bar). Each column represents the mean ± S.E.M. ⁄P < 0.01. (B)
Cultured medium was collected from shCont or shPP2A cells and subjected to ELISA. The ratio of Soluble RANKL (sRANKL) to OPG is represented as the relative value
compared to shCont cells. Each column represents mean ± S.E.M. values. ⁄P < 0.01.
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Fig. 2. Localization of NFATc1 in bone marrow macrophage cells. Bone marrow macrophage (A) and RAW264.7 (B) cells on coverslips were treated with the conditioned
medium collected from shCont and shPP2A cells. The cells were incubated with anti-NFATc1 antibody. NFATc1 was found to localize in the nuclei of cells treated with the
conditioned medium from shCont but not from shPP2A cells. Bar indicates 20 lm. (C) Bone marrow macrophage cells were treated with the conditioned medium from either
shCont or shPP2A cells. Cell lysates from the cells were collected and subjected to western blots analysis. Immunoblots were developed by using speciﬁc antibodies for
NFATc1 and b-actin.
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medium from shCont or shPP2A cells. NFATc1 translocation into
nucleus (yellow ﬂuorescent signal) was observed in the cells trea-
ted with the conditioned media from shCont cells, but not shPP2A
cells (Fig. 2B). Dephosphorylation of NFATc1 allows NFATc1 to
translocate and activate in the nucleus [10,13]. To further examine
phosphorylation status of NFATc1, the cell lysate was collected and
subjected to western blot analysis using NFATc1 speciﬁc antibody.
Fig. 2C shows that the conditionedmedia from shCont cells induced
dephosphorylation of NFATc1 proteins in RAW264.7 cells, which
can be followed by nuclear translocation. In contrast, phosphory-
lated status of NFATc1 (p-NFAT1c1) was still detected as around
120 kDa band in the RAW264.7 cells treated with the conditioned
medium from shPP2A cells.3.3. Conditioned medium from shPP2A cells does not induce the
expression of NFATc1-related osteoclastogenesis marker genes
We next investigated whether translocalization of NFATc1 re-
sults in differential expression of NFATc1-related genes. Total
RNA was extracted from bone marrow cells treated with the con-
ditioned medium from shCont and shPP2A cells. Real-time PCR
was performed for NFATc1-related genes that are involved in
osteoclast differentiation. Fig. 3 shows that expressions of cathep-
sin K and OSCAR were signiﬁcantly lower in bone marrow cells
treated with the conditioned medium from shPP2A cells com-
pared to those from shCont cells. The addition of recombinant
sRANKL (100 ng/ml) to the conditioned medium from shPP2A
cells dramatically restored NFATc1 translocation and the
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Fig. 3. Expression levels of cathepsin K and OSCAR in osteoclast precursor cells. (A) Bone marrowmacrophage cells were treated with the conditioned medium collected from
shCont or shPP2A cells for 24 h. Total RNA was isolated and subjected to real-time PCR by using speciﬁc primers for cathepsin K and OSCAR. Gene expression was normalized
to Gapdh and plotted as the relative value compared to shCont cells (white bar). Each column represents the mean ± S.E.M. ⁄P < 0.01. (B) Bone marrow macrophage cells on
coverslips were treated with the conditioned medium collected from shPP2A cells with or without sRANKL (100 ng/ml) for 1 h. The cells were stained with anti-NFATc1
antibody and Hoechst 33342. NFATc1 was found to localize in the nuclei of cells treated with the conditioned medium from shPP2A cells with sRANKL. Bar indicates 20 lm.
(C) Bone marrow macrophage cells were treated with the conditioned medium collected shPP2A cells with or without sRANKL (100 ng/ml) for 24 h. Total RNA was isolated
and subjected to real-time PCR by using speciﬁc primers for cathepsin K and OSCAR. Gene expression was normalized to Gapdh and plotted as the relative value compared to
shCont cells (white bar). Each column represents the mean ± S.E.M. ⁄P < 0.01.
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(Fig. 3B and C).
3.4. Conditioned medium from shPP2A cells does not induce TRAP-
positive multinuclear cells
Finally, to examine the effect of PP2A in osteoblasts to induce
TRAP-positive multinuclear cells, we treated bone marrow cells
with the conditioned medium from shCont cells or shPP2A cells.
Treatment with the conditioned medium from shCont cells in-
duced the formation of TRAP-positive multinuclear osteoclasts.
However, no effect was observed in the cells treated with theshCont
shPP2A
a b
c d
A
Fig. 4. TRAP-positive multinuclear cells induced by treatment with the conditioned med
derived from shCont (a, b) or shPP2A cells (c, d). The cells were ﬁxed and stained for TR
numbers of TRAP-positive multinuclear cells were counted. Bars indicate 50 lm. Each cconditioned medium from shPP2A cells (Fig. 4A). Fig. 4B shows
the number of TRAP-positive multinuclear cells in each well of a
96-well plate. The number of TRAP-positive multinuclear cells in
the bone marrow cells treated with the conditioned medium from
shPP2A cells was signiﬁcantly lower than that in the bone marrow
cells treated with the conditioned medium from shCont cells.
4. Discussion
Osteoblasts control bone metabolism not only by synthesizing
bone matrix proteins and regulating mineralization but also
by orchestrating the process of bone resorption through theTR
A
P-
po
si
tiv
e 
 
 
(ce
lls
/w
el
l)
shCont              shPP2A
*
B
ium. (A) Bone marrow macrophage cells were treated with the conditioned medium
AP expression. High-power magniﬁcation images are shown in (b) and (d). (B) The
olumn represents mean ± S.E.M. values. ⁄P < 0.01.
52 H. Okamura et al. / FEBS Letters 587 (2013) 48–53regulation of osteoclastogenesis [19,20]. However, there has been
no information about the relationship between PP2A Ca
expression in osteoblasts and osteoclastogenesis. Therefore, we
investigated whether PP2A Ca expression in osteoblasts can
play an important role in osteoclastogenesis by using PP2A
Ca-knocked-down osteoblasts (shPP2A).
In this study, we demonstrated that silencing of PP2A Ca in
osteoblasts decreased RANKL and increased OPG expression. In
agreement with our real-time PCR results, we also showed that
the sRANKL/OPG ratio in the culture medium was signiﬁcantly
decreased in shPP2A cells compared to control cells (shCont). The
balance of the RANKL/OPG ratio is known to be crucial for bone
homeostasis [7,8,21], since the ratio of RANKL/sRANKL to OPG pro-
duced by osteoblasts modulates osteoclast differentiation and
activity [9,22]. Increases in the ratio of RANKL/sRANKL to OPG
are expected to favor osteoclastogenesis, while decreases should
favor inhibition of osteoclastogenesis. Our present results indicate
that PP2A Ca can regulate the expression and production of
RANKL/sRANKL and OPG, leading us to hypothesize that PP2A Ca
in the osteoblasts is involved in osteoclastogenesis.
RANKL/sRANKL-RANK signaling induces various transcription
factors, including NFATc1, which can act as a positive modulator
in osteoclast differentiation [12,21,23]. In this study, we have
shown that NFATc1 translocation and dephosphorylation were in-
duced by the treatment of the conditioned medium from shCont,
but not shPP2A cells. This result indicates that reduction of PP2A
Ca in osteoblasts impairs its ability to induce NFATc1 dephospho-
rylation and translocation in osteoclast precursors.
NFATc1 induces the expression of target genes by binding to
NFAT-binding sites in the promoter region of genes such as TRAP,
cathepsin K, and OSCAR, which are important for osteoclast differ-
entiation or function [24,25]. A positive feedback loop exists during
late-stage osteoclastogenesis, in which NFATc1 induces OSCAR
expression leading to the activation of NFATc1 [25,26]. Consistent
with previous reports, we showed that the conditioned medium
from shCont cells induced cathepsin K and OSCAR, following
NFATc1 translocation. In contrast, the conditioned medium of
shPP2A cells failed to induce the expression of these genes in bone
marrow macrophage cells. However, the addition of recombinant
sRANKL dramatically recovered NFATc1 translocation and the
expression of NFATc1-related genes in the cells treated with the
conditioned medium from shPP2A cells. These results indicates
that the reduction of the ratio of RANKL/sRANKL to OPG in shPP2A
cells results in impairment of NFATc1 translocation and the
expression of NFATc1-related genes. Moreover, the number of
TRAP-positive multinuclear cells induced by the conditioned med-
ium from shPP2A cells was signiﬁcantly lower than that from
shCont cells. The same result was obtained when we co-cultured
bone marrow macrophage cells with shCont or shPP2A cells (data
not shown). These results indicate that reduction of PP2A in oste-
oblasts has a negative effect on osteoclastogenesis through the
down-regulation of NFATc1-related osteoclast marker genes.
In our previous study, administration of okadaic acid (OA), a
PP2A inhibitor, to the calvarial region in mice increased bone min-
eral density, mineral apposition, and bone thickness [17]. We con-
cluded in the previous report that reduction of PP2A activity in
osteoblasts by OA accelerates osteoblast differentiation, which in
turn leads to stimulate bone formation. In the present study, we
showed that inhibition of PP2A activity was involved in impair-
ment of osteoclastogenesis by regulating RANKL and OPG expres-
sion in osteoblasts. These observations may provide a new
explanation that the positive effect of OA on bone formation results
from an inhibitory effect on osteoclastogenesis. On the other hand,
it was reported that, in osteoclasts, the induction of PP2A by Toll-
like receptor 9 ligand blocks RANKL-induced osteoclast differenti-
ation through dephosphorylation of ERK and c-fos [27,28]. Thesereports and our ﬁndings imply that PP2A exert complicated and
pleiotropic effects on osteoblastogenesis and osteoclastogenesis,
respectively. Therefore, further studies are needed to investigate
a detailed molecular mechanism in osteoblast- and osteoclast-dif-
ferentiation controlled by PP2A.
In conclusion, we demonstrated that reduction of PP2A de-
creased the ratio of RANKL/sRANKL to OPG both at the mRNA
and protein level in osteoblasts. Moreover, reduction of PP2A in
osteoblasts failed to induce NFATc1 activation and osteoclasto-
genesis. Our present study provides the ﬁrst line of evidence that
PP2A Ca expression in osteoblasts plays a pivotal role in osteo-
clastogenesis via the regulation of NFATc1-related gene expression.Acknowledgment
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